BioCentury
ARTICLE | Clinical News

BioMarin completes Phase III enrollment

March 2, 2001 8:00 AM UTC

BioMarin (BMRN; SWX:BMRN) and partner Genzyme (GENZ) completed enrollment of a 45-patient Phase III study of Aldurazyme recombinant alpha-L-iduronidase enzyme to treat mucopolysaccharidosis-I (MPS-I),...